At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 519 enrolled
Drug / intervention
Peficitinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3 Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis Who Had an Inadequate Response to MTX
In Brief
A Phase 3 clinical trial evaluating Peficitinib, Placebo, and 1 other intervention for Rheumatoid Arthritis. Completed, enrolled 519 participants across 146 sites.
Detailed Summary
The objective of this study was to verify the efficacy of ASP015K versus placebo administrated in combination with methotrexate (MTX) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to MTX
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedDec 2014
Primary CompletionJun 2017
Study CompletionNov 2017
TodayJul 2026
First PostedDec 3, 2014
Enrollment StartJul 25, 2014
Primary CompletionJun 20, 2017
Study CompletionNov 28, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 11.6 years ago
Interventions
Peficitinibdrug
oral tablet
Placebodrug
oral tablet
Methotrexatedrug
Oral tablet/capsule